시장보고서

상품코드

2075172

폐암 진단 및 스크리닝 시장 : 검사 유형별, 암 유형별, 최종사용자별, 지역별

Lung Cancer Diagnostic and Screening Market, By Test Type, By Cancer Type, By End User, By Geography

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,953,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,817,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 15,453,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폐암 진단·스크리닝 시장은 2026년에 32억 8,780만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 65억 3,040만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 10.3%로 성장할 것으로 전망되고 있습니다.

리포트 범위		리포트 상세
기준연도 :	2025년	2026년 시장 규모 :	32억 8,780만 달러
과거 데이터 기간 :	2020-2024년	예측 기간 :	2026-2033년
2026-2033년 예측 기간의 CAGR :	10.30%	2033년 시장 규모 예측 :	65억 3,040만 달러

폐암은 폐에서 발생하며, 림프절이나 뇌 등 체내의 다른 장기로 전이될 수 있습니다. 또한 다른 장기의 암이 폐로 전이되기도 합니다. 암세포가 한 장기에서 다른 장기로 퍼지는 것을 ‘전이'라고 부릅니다. 폐암은 일반적으로 소세포폐암과 비소세포폐암이라는 두 가지 주요 유형으로 분류됩니다. 이러한 폐암들은 증식 방식이 다르며, 치료법도 다릅니다. 미국 암 협회에 따르면 비소세포폐암은 소세포폐암보다 더 흔합니다. 폐암의 증상은 사람마다 다릅니다. 폐와 관련된 증상이 나타나는 사람이 있는 반면, 폐암이 신체의 다른 부위로 퍼진(전이된) 사람 중에는 해당 부위에 특정한 증상이 나타나는 경우도 있습니다. 폐암의 증상으로는 악화되는 기침이나 오래 지속되는 기침, 가슴 통증, 숨가쁨, 천명음, 객혈, 지속적인 심한 피로감, 원인 불명의 체중 감소 등이 있습니다.

미국 질병통제예방센터(CDC)에 따르면 폐암은 미국에서 세 번째로 많이 발생하는 암입니다. 미국에서는 다른 어떤 암보다 폐암으로 사망하는 사람이 더 많습니다. 예를 들어 미국암협회(American Cancer Society)에 따르면 2018년에는 약 15만 4,050명의 미국인이 폐암으로 사망할 것으로 예상되며, 이는 전체 암 사망자의 약 25%를 차지합니다. 의사는 바이오마커 검사, 영상 검사, 생검 등 폐암을 확진하기 위해 여러 가지 검사를 실시할 수 있습니다.

시장 역학

예측 기간 중, 새로운 선별 검사에 대한 규제 당국의 승인 및 시장 출시가 전 세계 폐암 진단·선별 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2020년 8월, 미국 식품의약국(FDA)은 치사율이 높은 전이성 비소세포폐암(NSCLC) 환자 중 상피성장인자 수용체(EGFR) 유전자의 특정 유형 변이를 가진 환자를 식별하기 위해 차세대 염기서열 분석(NGS) 기술을 활용하는 액체생검 동반 진단제를 승인했습니다.

그러나 폐암 선별 검사의 높은 비용도 시장 성장을 저해하는 요인이 될 것으로 예상됩니다. 예를 들어 미국 국제의학위원회(ABIM)에 따르면 CT 촬영 비용은 300달러 이상입니다. 이 검사는 정기적으로 받아야 합니다.

본 조사의 주요 특징:

본 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
본 조사에서는 다음의 매개변수를 바탕으로 전 세계 폐암 진단 및 선별 검사 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략입니다.
이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 정부의 정책, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
이 '세계의 폐암 진단 및 선별 검사 시장' 보고서는 투자자, 제품 제조업체, 유통업체, 공급업체를 비롯해 조사·컨설팅 회사, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 3,287.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.30%	2033 Value Projection:	USD 6,530.4 Mn

Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types such as small cell and non-small cell. These types of lung cancer grow differently and are treated differently. According American Cancer Society non-small cell lung cancer is more common than small cell lung cancer. Different people have different symptoms for lung cancer. Some people have symptoms related to the lungs. Some people whose lung cancer has spread to other parts of the body (metastasized) have symptoms specific to that part of the body. Lung cancer symptoms may include coughing that gets worse or prolonged coughing, chest pain, shortness of breath, wheezing, coughing of blood, feeling very tired all the time, weight loss with no known cause.

According to the Centers for Disease Control and Prevention, lung cancer is the third most common cancer in the U.S. Most people in the U.S. die from lung cancer than any other type of cancer. For instance, According American Cancer Society, an estimated 154,050 Americans were expected to die from lung cancer in 2018, accounting for approximately 25% of all cancer deaths. Doctors may perform several tests to confirm lung cancer such as biomarker test, imaging test, and biopsy.

Market Dynamics

Regulatory approvals and launches of new screening test are expected to propel growth of the global lung cancer diagnostic and screening market during the forecast period. For instance, in August 2020, the U.S. Food and Drug Administration approved the liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

However, high cost of lung cancer screening test is also expected to limit the market growth. For instance, according to the American Board of International medicine a CT scan costs US$ 300 and more. These test one need to take periodically.

Key features of the study:

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global lung cancer diagnostic and screening market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Abbott, Illumina, Inc, Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics, Inc. F. Hoffmann-La Roche Ltd., Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global lung cancer diagnostic and screening market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for lung cancer diagnostic and screening market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Lung Cancer Diagnostic and Screening market, By Test Type (Revenue, USD Mn, 2021 - 2033)
Biomarkers Tests
- EGFR Mutation Test
- KRAS Mutation Test
- ALK Test
- HER2 Test
- Others
Imaging Tests
- Computed Tomography (CT) Scan
- Positron Emission Tomography (PET) Scan
- Chest X-RAY
- Others
Biopsy
- Needle Biopsy
- Bronchoscopy Biopsy
- Open Biopsy
- Others
Global Lung Cancer Diagnostic and Screening Market, By Cancer Type (Revenue, USD Mn, 2021 - 2033)
Non-small cell lung cancer
Small Cell Lung Cancer
Global Lung Cancer Diagnostic and Screening Market, By End User (Revenue, USD Mn, 2021 - 2033)
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Global Lung Cancer Diagnostic and Screening Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country:
  - U.S.
  - Canada
- By Test Type:
  - Biomarkers Tests
  - Imaging Tests
  - Biopsy
- By Cancer Type:
  - Non-small cell lung cancer
  - Small Cell Lung Cancer
- By End User:
  - Hospitals
  - Independent Diagnostic Laboratories
  - Diagnostic Imaging Centers
  - Cancer Research Institutes
Europe
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
- By Test Type:
  - Biomarkers Tests
  - Imaging Tests
  - Biopsy
- By Cancer Type:
  - Non-small cell lung cancer
  - Small Cell Lung Cancer
- By End User:
  - Hospitals
  - Independent Diagnostic Laboratories
  - Diagnostic Imaging Centers
  - Cancer Research Institutes
Asia Pacific
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
- By Test Type:
  - Biomarkers Tests
  - Imaging Tests
  - Biopsy
- By Cancer Type:
  - Non-small cell lung cancer
  - Small Cell Lung Cancer
- By End User:
  - Hospitals
  - Independent Diagnostic Laboratories
  - Diagnostic Imaging Centers
  - Cancer Research Institutes
Latin America
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- By Test Type:
  - Biomarkers Tests
  - Imaging Tests
  - Biopsy
- By Cancer Type:
  - Non-small cell lung cancer
  - Small Cell Lung Cancer
- By End User:
  - Hospitals
  - Independent Diagnostic Laboratories
  - Diagnostic Imaging Centers
  - Cancer Research Institutes
Middle East
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
- By Test Type:
  - Biomarkers Tests
  - Imaging Tests
  - Biopsy
- By Cancer Type:
  - Non-small cell lung cancer
  - Small Cell Lung Cancer
- By End User:
  - Hospitals
  - Independent Diagnostic Laboratories
  - Diagnostic Imaging Centers
  - Cancer Research Institutes
Africa
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
- By Test Type:
  - Biomarkers Tests
  - Imaging Tests
  - Biopsy
- By Cancer Type:
  - Non-small cell lung cancer
  - Small Cell Lung Cancer
- By End User:
  - Hospitals
  - Independent Diagnostic Laboratories
  - Diagnostic Imaging Centers
  - Cancer Research Institutes
Company Profiles
Abbott
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Illumina, Inc
Thermo Fischer Scientific
QIAGEN
Quest Diagnostics Incorporated
NeoGenomics
NanoString
Myriad Genetics, Inc.
Hoffmann-La Roche Ltd
Danaher
Agilent Technologies, Inc.
AstraZeneca
Sanofi
Janssen Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Test Type
- Market Snippet, By Cancer Type
- Market Snippet, By End User
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Biomarkers Test
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
  - EGFR Mutation Test
  - KRAS Mutation Test
  - ALK Test
  - HER2 Test
  - Others
Imaging Test
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
  - Computed Tomography (CT) scan
  - Positron Emission Tomography (PET) scan
  - Chest X-Ray
  - Others
Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends

5. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Non-small cell lung cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends
Small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
- Segment Trends

6. Global Lung Cancer Diagnostic and Screening Market, By End User, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Associated Labs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
Independent Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
Cancer Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Mn)

7. Global Lung Cancer Diagnostic and Screening Market, By Region, 2021-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Test Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Cancer Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Abbott
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Amgen Inc.,
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Illumina, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Thermo Fisher Scientific Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Lepu Medical Technology(Beijing)Co.,Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AstraZeneca
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- F. Hoffmann-La Roche Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Laboratory Corporation of America Holdings.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Agilent Technologies, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- QIAGEN
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Quest Diagnostics Incorporated.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- NeoGenomics Laboratories.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Myriad Genetics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- GRAIL, LLC.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- DELFI Diagnostics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

9. Section

References
Research Methodology
About us and Sales Contact

폐암 진단 및 스크리닝 시장 : 검사 유형별, 암 유형별, 최종사용자별, 지역별

Lung Cancer Diagnostic and Screening Market, By Test Type, By Cancer Type, By End User, By Geography

시장 역학

본 조사의 주요 특징:

목차

제1장 조사 목적과 전제조건

제2장 시장 전망

제3장 시장 역학·규제·동향 분석

제4장 세계의 폐암 진단·스크리닝 시장 : 테스트 유형별, 2021-2033년

제5장 세계의 폐암 진단·스크리닝 시장 : 암 유형별, 2021-2033년

제6장 세계의 폐암 진단·스크리닝 시장 : 최종사용자별, 2021-2033년

제7장 세계의 폐암 진단·스크리닝 시장 : 지역별, 2021-2033년

제8장 경쟁 구도

제9장 섹션

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2021-2033, (US$ Mn)

5. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2021-2033, (US$ Mn)

6. Global Lung Cancer Diagnostic and Screening Market, By End User, 2021-2033, (US$ Mn)

7. Global Lung Cancer Diagnostic and Screening Market, By Region, 2021-2033, (US$ Mn)

8. Competitive Landscape

9. Section

폐암 진단 및 스크리닝 시장 : 검사 유형별, 암 유형별, 최종사용자별, 지역별

Lung Cancer Diagnostic and Screening Market, By Test Type, By Cancer Type, By End User, By Geography

시장 역학

본 조사의 주요 특징:

목차

제1장 조사 목적과 전제조건

제2장 시장 전망

제3장 시장 역학·규제·동향 분석

제4장 세계의 폐암 진단·스크리닝 시장 : 테스트 유형별, 2021-2033년

제5장 세계의 폐암 진단·스크리닝 시장 : 암 유형별, 2021-2033년

제6장 세계의 폐암 진단·스크리닝 시장 : 최종사용자별, 2021-2033년

제7장 세계의 폐암 진단·스크리닝 시장 : 지역별, 2021-2033년

제8장 경쟁 구도

제9장 섹션

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2021-2033, (US$ Mn)

5. Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2021-2033, (US$ Mn)

6. Global Lung Cancer Diagnostic and Screening Market, By End User, 2021-2033, (US$ Mn)

7. Global Lung Cancer Diagnostic and Screening Market, By Region, 2021-2033, (US$ Mn)

8. Competitive Landscape

9. Section

원하시는 정보를 찾아 드릴까요?